vs
Side-by-side financial comparison of Commercial Vehicle Group, Inc. (CVGI) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
Commercial Vehicle Group, Inc. is the larger business by last-quarter revenue ($154.8M vs $86.8M, roughly 1.8× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -5.2%). Commercial Vehicle Group, Inc. produced more free cash flow last quarter ($8.7M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -10.8%).
WABCO Holdings, Inc. was a U.S.-based provider of electronic braking, stability, suspension and transmission automation systems for heavy-duty commercial vehicles. In 2007, the Vehicle Control Systems was spun off as WABCO Holdings Inc., an American provider of electronic braking, stability, suspension and transmission automation systems for heavy-duty commercial vehicles. Their products are present in many commercial vehicles such as trucks, buses, trailers and off-highway vehicles but they ...
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CVGI vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $154.8M | $86.8M |
| Net Profit | — | — |
| Gross Margin | 9.7% | 67.4% |
| Operating Margin | -1.2% | -84.7% |
| Net Margin | — | — |
| Revenue YoY | -5.2% | 17.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $154.8M | $86.8M | ||
| Q3 25 | $152.5M | $67.5M | ||
| Q2 25 | $172.0M | $60.0M | ||
| Q1 25 | $169.8M | $49.3M | ||
| Q4 24 | $163.3M | $73.7M | ||
| Q3 24 | $171.8M | $58.6M | ||
| Q2 24 | $193.7M | $31.1M | ||
| Q1 24 | $194.6M | $715.0K |
| Q4 25 | — | — | ||
| Q3 25 | $-7.1M | $-91.3M | ||
| Q2 25 | $-4.8M | $-111.7M | ||
| Q1 25 | $-4.3M | $-116.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $9.5M | $-83.5M | ||
| Q2 24 | $-1.6M | $-97.1M | ||
| Q1 24 | $2.9M | $-113.0M |
| Q4 25 | 9.7% | 67.4% | ||
| Q3 25 | 10.5% | 43.0% | ||
| Q2 25 | 11.4% | 5.5% | ||
| Q1 25 | 10.5% | -0.8% | ||
| Q4 24 | 8.0% | 68.7% | ||
| Q3 24 | 9.6% | 46.2% | ||
| Q2 24 | 10.6% | -0.8% | ||
| Q1 24 | 11.9% | — |
| Q4 25 | -1.2% | -84.7% | ||
| Q3 25 | -0.7% | -140.7% | ||
| Q2 25 | 0.5% | -189.8% | ||
| Q1 25 | 0.8% | -245.8% | ||
| Q4 24 | -3.2% | -117.5% | ||
| Q3 24 | -0.6% | -152.1% | ||
| Q2 24 | 0.5% | -327.6% | ||
| Q1 24 | 2.3% | -16464.6% |
| Q4 25 | — | — | ||
| Q3 25 | -4.6% | -135.3% | ||
| Q2 25 | -2.8% | -186.2% | ||
| Q1 25 | -2.5% | -235.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.5% | -142.7% | ||
| Q2 24 | -0.8% | -312.2% | ||
| Q1 24 | 1.5% | -15800.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-0.33 | ||
| Q1 25 | — | $-0.36 | ||
| Q4 24 | — | $-0.24 | ||
| Q3 24 | — | $-0.28 | ||
| Q2 24 | $-0.05 | $-0.34 | ||
| Q1 24 | $0.09 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | $104.9M | — |
| Stockholders' EquityBook value | $133.4M | $698.6M |
| Total Assets | $391.7M | $913.2M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $412.5M | ||
| Q1 24 | — | $356.2M |
| Q4 25 | $104.9M | — | ||
| Q3 25 | $108.2M | — | ||
| Q2 25 | $118.2M | — | ||
| Q1 25 | $117.4M | — | ||
| Q4 24 | $135.5M | — | ||
| Q3 24 | $128.8M | — | ||
| Q2 24 | $142.0M | — | ||
| Q1 24 | $155.7M | — |
| Q4 25 | $133.4M | $698.6M | ||
| Q3 25 | $136.5M | $702.3M | ||
| Q2 25 | $142.6M | $698.5M | ||
| Q1 25 | $136.7M | $767.9M | ||
| Q4 24 | $135.6M | $710.4M | ||
| Q3 24 | $179.3M | $773.5M | ||
| Q2 24 | $169.6M | $768.5M | ||
| Q1 24 | $175.5M | $680.0M |
| Q4 25 | $391.7M | $913.2M | ||
| Q3 25 | $400.3M | $904.9M | ||
| Q2 25 | $429.8M | $907.4M | ||
| Q1 25 | $419.8M | $966.7M | ||
| Q4 24 | $424.6M | $910.4M | ||
| Q3 24 | $495.3M | $991.1M | ||
| Q2 24 | $503.2M | $964.3M | ||
| Q1 24 | $509.2M | $869.8M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 0.83× | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | 1.00× | — | ||
| Q3 24 | 0.72× | — | ||
| Q2 24 | 0.84× | — | ||
| Q1 24 | 0.89× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $12.3M | $-52.6M |
| Free Cash FlowOCF − Capex | $8.7M | $-61.9M |
| FCF MarginFCF / Revenue | 5.6% | -71.3% |
| Capex IntensityCapex / Revenue | 2.3% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $34.0M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $12.3M | $-52.6M | ||
| Q3 25 | $-1.7M | $-78.7M | ||
| Q2 25 | $18.9M | $-67.4M | ||
| Q1 25 | $15.2M | $-103.7M | ||
| Q4 24 | $-26.6M | $-73.3M | ||
| Q3 24 | $-17.1M | $-59.0M | ||
| Q2 24 | $12.6M | $-98.4M | ||
| Q1 24 | $-2.4M | $-122.3M |
| Q4 25 | $8.7M | $-61.9M | ||
| Q3 25 | $-3.5M | $-89.5M | ||
| Q2 25 | $17.4M | $-74.9M | ||
| Q1 25 | $11.4M | $-109.9M | ||
| Q4 24 | $-30.6M | $-77.5M | ||
| Q3 24 | $-20.3M | $-61.3M | ||
| Q2 24 | $6.4M | $-98.9M | ||
| Q1 24 | $-7.4M | $-126.5M |
| Q4 25 | 5.6% | -71.3% | ||
| Q3 25 | -2.3% | -132.7% | ||
| Q2 25 | 10.1% | -124.9% | ||
| Q1 25 | 6.7% | -222.8% | ||
| Q4 24 | -18.7% | -105.1% | ||
| Q3 24 | -11.8% | -104.6% | ||
| Q2 24 | 3.3% | -317.9% | ||
| Q1 24 | -3.8% | -17685.3% |
| Q4 25 | 2.3% | 10.7% | ||
| Q3 25 | 1.2% | 16.1% | ||
| Q2 25 | 0.9% | 12.4% | ||
| Q1 25 | 2.2% | 12.6% | ||
| Q4 24 | 2.4% | 5.7% | ||
| Q3 24 | 1.9% | 3.9% | ||
| Q2 24 | 3.2% | 1.4% | ||
| Q1 24 | 2.6% | 583.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.79× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.80× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CVGI
| Global Seating | $70.7M | 46% |
| Global Electrical Systems | $49.7M | 32% |
| Trim Systems And Components | $34.4M | 22% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
